臨床神経学

第50回日本神経学会総会

<シンポジウム12―2>末梢神経疾患研究の現在
家族性アミロイドポリニューロパチー(FAP)の治療戦略

池田 修一

信州大学医学部脳神経内科, リウマチ・膠原病内科〔〒390-8621 松本市旭3-1-1〕

Familial amyloid polyneuropathy (FAP) was long considered to be an incurable disease, but a new therapeutic approach was developed 15 years ago. As the liver produces most of the transthyretin (TTR) in serum, it was assumed that the replacement of a liver expressing an abnormal TTR gene should stop the production of the variant TTR, the serum amyloid precursor in FAP. Until now about 1,500 FAP patients underwent liver transplantation, and the 10-year-survival rate is about 77%. After operation the progression of FAP symptoms certainly stopped, and patients who were in an early stage of the disease and underwent successful operations showed considerable improvement in their quality of life. Electrophysiological study of peripheral nerve function has demonstrated that liver transplantation can halt the progression of peripheral neuropathy in FAP patients, and histopathological regression of amyloid deposits was seen on the patients with long post-transplatation courses. Pharmacological therapies have been considered for FAP patients and among them, diflunisal, one of non-steroidal anti-inflammatory drugs, is very promising. TTR tetramer dissociation is an initial step for the process of TTR-derived amyloid fibril formation associated with FAP and diflinisal can inhibit this process by stabilization of the TTR tetramer. Clinical trial of this drug for FAP patients is now going worldwide.
Full Text of this Article in Japanese PDF (266K)

(臨床神経, 49:953−955, 2009)
key words:アミロイド, アミロイド・ニューロパチー, トランスサイレチン, 肝移植, アミロイド退縮

(受付日:2009年5月22日)